Europe Self Injections Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 11.03 Billion |
 Market Size (Forecast Year) |
USD 22.52 Billion |
 CAGR |
% |
| Major Markets Players |
欧洲自我注射市场细分，按产品类型（自我注射设备和自我注射配方）、剂型（单剂量和多剂量）、给药途径（皮下、肌肉内和其他）、应用（自身免疫性疾病疼痛管理、急救药物、肿瘤学、激素紊乱和其他）、年龄组（成人、老年和儿童）、性别（男性和女性）、分销渠道（直接招标、医院药房、网上药房和其他）– 行业趋势和预测到 2031 年
自我注射市场分析
欧洲自我注射市场受到慢性病患病率上升、自我注射技术进步、患者自主性提高以及移动医疗应用兴起的推动。该市场的特点是关键参与者的存在、持续的研究和开发以及战略合作。有利的监管环境和不断增加的医疗保健支出也支持了市场的扩张。自我注射设备，包括自动注射器、笔式注射器和可穿戴注射器，因其方便、易用以及能够通过允许患者在家中自行给药来提高患者依从性，从而减少频繁就医的需要，而变得越来越受欢迎。跟踪和监控患者依从性的联网设备等技术创新进一步推动了市场增长。
自我注射市场规模
2023 年欧洲自我注射市场规模价值 110.3 亿美元，预计到 2031 年将达到 225.2 亿美元，2024 年至 2031 年预测期内的复合年增长率为 9.5%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
自我注射市场趋势
“更加关注用户友好型和一次性设备”
欧洲自我注射市场的一个主要趋势是对用户友好型一次性设备的需求不断增长。随着越来越多的患者管理糖尿病、类风湿性关节炎和多发性硬化症等慢性病，对易于使用的自我给药系统的需求也日益增长。自动注射器和预充式注射器等自我注射设备旨在通过简化注射过程来提高患者的依从性。这一趋势与更广泛的家庭护理转变相一致，鼓励患者更好地控制自己的治疗方案，减少频繁前往医疗机构的需要。
此外，技术进步也推动了该市场的创新。制造商正在将剂量跟踪和实时反馈等智能功能融入自我注射设备中。这些功能对于需要频繁注射的患者尤其有益，因为它们可以提高注射的精准度并降低注射不足或过量的风险。安全性、便利性和数字集成的增强可能会加速欧洲自我注射设备的普及，特别是在患者人数不断增长且医疗保健意识不断增强的地区。
报告范围和自我注射市场细分
|
属性 |
自我注射关键市场洞察 |
|
涵盖的领域 |
|
|
覆盖国家 |
英国、德国、法国、西班牙、意大利、比利时、俄罗斯、瑞士、荷兰、土耳其、丹麦、瑞典、挪威、波兰、芬兰和欧洲其他地区 |
|
主要市场参与者 |
拜耳公司 (德国)、UCB Pharma (比利时)、益普生生物制药公司 (法国)、梯瓦制药工业有限公司 (以色列)、Recipharm AB (瑞典)、SCHOTT Pharma (德国)、礼来公司 (美国)、阿斯利康公司 (英国)、武田制药有限公司 (日本)、诺华公司 (瑞士)、辉瑞公司 (美国)、赛诺菲公司 (法国)、艾伯维公司 (美国)、百健公司 (美国)、YPSOMED (瑞士)、博士伦制药公司 (加拿大)、默克公司 (美国)、安进公司 (美国)、强生服务公司 (美国)、PharmaJet (美国)、Societe Industrielle de Sonceboz SA (瑞士)、泰尔茂株式会社 (日本)、Haselmeier (德国)、Owen Mumford (英国)、Midas Pharma GmbH (德国)、BD (美国)、 Phillips-Medisize（美国）、West Pharmaceutical Services（美国）、Gerresheimer AG（德国）、Nemera（法国）、Oval Medical Technologies Ltd. (SMC Limited)（英国）、SHL Medical AG（瑞士）、Novo Nordisk A/S（丹麦）、AptarGroup, Inc.（美国）、Boehringer Ingelheim International GmbH（德国）、F. Hoffmann-La Roche Ltd（瑞士）和 GSK plc（英国）等 |
|
市场机会 |
|
|
增值数据信息集 |
除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解之外，Data Bridge Market Research 策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。 |
自我注射市场定义
欧洲自我注射市场是指专注于开发、制造和分销设备和技术的行业，使患者能够自行用药，而无需医疗保健专业人员的直接参与。这些设备（例如自动注射器、预充式注射器、笔式注射器和可穿戴注射器）旨在提供各种治疗，包括生物制剂、胰岛素、激素和糖尿病、类风湿性关节炎和多发性硬化症等慢性病的治疗。该市场受到多种因素的推动，包括慢性病患病率的不断上升、对家庭医疗保健的日益偏好、对生物制剂和个性化医疗的需求不断增长，以及强调用户友好型设计、安全性和可靠性的药物输送技术的进步。
自我注射市场动态
驱动程序
- 慢性病患病率上升
糖尿病、关节炎和多发性硬化症等慢性病的日益流行是自我注射市场的主要驱动力。患有这些疾病的患者经常需要持续服药，因此自我注射设备既方便又必不可少。随着全球人口老龄化，对有效的家庭治疗方案的需求持续上升。自我注射系统使患者能够独立管理病情，大大减少了去医院就诊的需要。这种转变不仅提高了患者的依从性和生活质量，还减轻了医疗保健系统的负担，推动了市场的进一步增长。对个性化医疗保健解决方案的日益关注支持了自我注射技术的扩展，满足了寻求更大治疗方案自主权的多样化患者群体的需求。
例如，
2024 年 1 月，根据 NCBI 发表的文章，糖尿病和心脏病等慢性疾病是全球发病率和死亡率的主要原因，预计到 2030 年成本将达到 47 万亿美元。因此，糖尿病等慢性疾病的流行是市场发展的驱动力。
- 自我注射的技术进步
医疗技术的最新创新促成了先进的自我注射设备的诞生，这些设备优先考虑用户友好性和效率。自动注射器、预填充注射器和与移动应用程序集成的智能设备等功能通过提供实时反馈和提醒，显著提升了用户体验。这些改进提高了药物输送的准确性，降低了出错的可能性，使自我注射对患者更具吸引力。随着医疗保健日益转向以患者为中心的模式，对这些技术先进的解决方案的需求预计将上升。这一趋势可能会推动自我注射市场向前发展，满足寻求更大自主权和改善健康状况管理的患者的需求。这些创新不仅可以提高患者满意度，而且有助于改善整体健康结果。
例如，
根据 2023 年 10 月在 Frederick Furness Publishing 上发表的文章，它探索了创新解决方案，以应对注射高粘度药物的挑战，而这些药物通常很难通过传统设备输送。通过强调技术进步，它讨论了改进的注射器设计和自动输送系统如何提高自我注射的便利性和有效性，从而推动市场增长。
机会
- 政府推动自我注射
政府推动自我注射疗法的举措为全球自我注射市场带来了重大机遇。许多政府都致力于加强以患者为中心的医疗保健，减轻负担过重的医疗保健系统的压力。为了实现这一目标，一些国家医疗保健机构正在积极鼓励自我注射实践，为自我注射设备提供教育计划、补贴和监管支持。这些举措旨在使患者能够在家中管理慢性病，改善农村或医疗服务不足地区的治疗机会，减少医院就诊次数。此外，自我注射设备和药物的优惠报销政策进一步激励了患者和制造商。政府以资助创新自我注射技术研发的形式提供支持，同时简化了监管审批流程，加速了更安全、更用户友好的设备的普及。这种日益增长的政府支持通过为自我注射的采用创造有利环境来促进市场扩张，最终促进制造商和医疗保健提供商的增长潜力。
例如，
2023 年 10 月，根据联合国人口基金 (UNFPA) 发布的信息，联合国人口基金是致力于改善全球生殖健康和孕产妇健康的联合国机构，推动将注射用甲羟孕酮醋酸酯 - 皮下注射 (DMPA-SC) 作为自我注射避孕选择纳入印度国家计划生育计划，这是一个有希望且适时的机会，在解决妇女未满足的避孕需求方面发挥着至关重要的作用，特别是那些在获取避孕药具方面面临诸多障碍的弱势群体。自我注射在增强和多样化选择、促进自我护理实践方面发挥着至关重要的作用。
- 加强自我注射的研究和开发
通过推动创新以满足患者和医疗保健系统不断变化的需求，增加自我注射技术的研发 (R&D) 是全球自我注射市场的关键机遇。新兴的进步专注于创造更直观、用户友好的设备，以提高安全性、便利性和患者依从性。这些创新包括开发具有数字健康功能的智能注射器、无针系统和旨在更易于操作和减轻疼痛的自动注射器。此外，研发正在扩大可自我注射的注射药物范围，特别是在生物制剂、胰岛素和癌症治疗等领域，这增加了市场潜力。连接功能的集成使患者能够与医疗保健提供者共享实时数据，进一步增强了个性化的治疗体验，并与全球向以患者为中心的护理转变保持一致。随着制药公司和设备制造商对尖端技术的投资，这些进步不仅拓宽了自我注射设备的应用范围，而且还推动了采用并开辟了全球市场的新增长途径。
例如，
2023 年 5 月，根据 Springer 发表的文章，由 PHC Corporation（日本东京）开发的电动机械自动注射器 SMARTCLIC/CLICWISE 注射装置最近推出，用于皮下注射生物疗法。该设备的研发计划经过战略性设计，旨在打造一款用户友好、多用途的自动注射器，专门用于单个患者应用。这项创新旨在为患者和护理人员提供先进的给药选择，超越传统的自我注射方法，例如带有空注射器的药瓶、预充笔或注射器以及早期的自动注射器型号。
限制/挑战
- 自我注射器成本高昂
自我注射器的高成本限制了许多患者和医疗服务提供者的可及性，严重制约了全球自我注射市场的发展。尽管这些设备使用方便，可以减少就诊次数，但自动注射器和可穿戴系统等先进自我注射设备的价格昂贵，大部分人都负担不起，尤其是低收入地区或没有全面保险覆盖的人。这种经济障碍往往导致患者对处方治疗的依从性降低，因为许多人买不起长期使用所需的设备。此外，医疗系统可能不愿投资这些高成本的解决方案，这进一步减缓了这些解决方案的采用和市场渗透。因此，解决可负担性问题对于扩大自我注射技术的覆盖面和有效性至关重要。
例如，
2022 年 7 月，根据 NCBI 发表的文章，对于有过敏反应风险的患者来说，肾上腺素自动注射器的高昂成本对获得这种救命治疗构成了重大障碍。2014 年至 2020 年间，领先的自动注射器品牌 EpiPen 的标价上涨了两倍，而私人保险个人的年度自付费用则翻了一番。2019 年，每两包 Auvi-Q 的平均自付费用为 736 美元，品牌 EpiPen 为 63 美元，非品牌替代品仅为 10 美元。总体而言，2019 年，96,073 名患者（50.8%）的肾上腺素自动注射器年度自付费用为 200 美元，而 11,863 名患者（9.5%）的自付费用超过 500 美元。自我注射的高成本严重影响了患者获得和坚持必要的治疗。
- 自我注射设备的监管障碍和适当培训需求
监管障碍和对适当培训的需求是全球自我注射市场的主要制约因素，减缓了产品的可用性和采用。严格的法规和不同国家的审批程序各不相同，可能会延迟创新型自我注射设备的推出，因为制造商必须通过复杂且耗时的审批途径。这不仅阻碍了创新，也限制了这些产品的全球影响力。此外，即使获得监管部门批准，对适当培训的需求也成为一个障碍。自我注射设备要求患者和医疗保健提供者熟练掌握其使用方法，以确保安全性和有效性。如果没有全面的培训计划，患者可能会误用设备，导致剂量不当、健康风险和治疗依从性降低。医疗保健提供者还必须投入时间和资源来教育患者，这对已经捉襟见肘的医疗保健系统来说可能是一个负担。缺乏广泛的培训基础设施，尤其是在发展中地区，进一步限制了自我注射市场的潜在增长。因此，监管复杂性和患者教育需求都是阻碍市场扩张的关键因素。
例如，
2022年12月，根据NCBI发表的文章，笔式注射器的设计受到包括美国食品药品管理局在内的各政府机构的严格监管，必须遵守ISO 11608和ISO 60601等行业标准。这些法规要求进行广泛的测试，以确保输送的剂量与设定的剂量相匹配，尤其是对于多剂量笔式注射器。此外，制造商必须对设备和配方的所有组件进行生物相容性测试，评估潜在的可浸出物或可萃取物及其对胰岛素配方的影响。其他监管考虑因素包括保质期稳定性、环境条件对设备性能的影响、灭菌、可用性测试和目视检查能力。对于带有电子元件的智能笔，测试还必须考虑在各种环境条件下（例如热量和湿度）的性能，以确保安全性和准确性。
本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
自我注射市场范围
市场根据产品类型、剂型、给药途径、应用、年龄组、性别和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
产品类型
- 自我注射装置
- 自动注射器
- 一次性的
- 可重复使用的
- 笔式注射器
- 一次性的
- 可重复使用的
- 可穿戴注射器
- 一次性的
- 可重复使用的
- 无针注射器
- 一次性的
- 可重复使用的
- 自动注射器
- 自注射配方
剂型
- 单剂量
- 多剂量
给药途径
- 皮下
- 肌肉内
- 其他的
应用
年龄组
- 成人
- 老年
- 儿科
性别
- 男性
- 女性
分销渠道
- 直接招标
- 医院药房
- 网上药店
- 其他的
自我注射市场区域分析
对市场进行分析，并按国家、产品类型、剂型、给药途径、应用、年龄组、性别和分销渠道提供市场规模洞察和趋势。
市场覆盖的国家包括英国、德国、法国、西班牙、意大利、比利时、俄罗斯、瑞士、荷兰、土耳其、丹麦、瑞典、挪威、波兰、芬兰和欧洲其他地区。
由于德国医疗保健基础设施不断扩大、慢性病发病率不断上升以及患者对自我护理解决方案的意识不断提高，预计德国将主导市场。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
自我注射市场份额
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在市场上运营的自我注射市场领导者是：
- 拜耳公司（德国）
- UCB 制药公司（比利时）
- Ipsen Biopharmaceuticals, Inc.（法国）
- 梯瓦制药工业有限公司 (以色列)
- Recipharm AB（瑞典）
- 肖特制药（德国）
- 礼来（美国）
- 阿斯利康（英国）
- 武田药品工业株式会社 (日本)
- 诺华公司（瑞士）
- 辉瑞公司（美国）
- 赛诺菲（法国）
- 艾伯维 (美国)
- Biogen（美国）
- YPSOMED（瑞士）
- Bausch Health Companies Inc.（加拿大）
- 默克公司（美国）
- 安进公司 (美国)
- 强生服务公司（美国）
- PharmaJet（美国）
- Societe Industrielle de Sonceboz SA（瑞士）
- 泰尔茂株式会社 (日本)
- 哈泽尔迈尔（德国）
- 欧文·芒福德（英国）
- Midas Pharma GmbH（德国）
- BD（美国）
- Phillips-Medisize（美国）
- West Pharmaceutical Services（美国）
- Gerresheimer AG（德国）
- Nemera（法国）
- Oval Medical Technologies Ltd.（SMC Limited）（英国）
- SHL Medical AG（瑞士）
- 诺和诺德公司（丹麦）
- AptarGroup, Inc.（美国）
- 勃林格殷格翰国际有限公司 (德国)
- F. Hoffmann-La Roche Ltd（瑞士）
- 葛兰素史克公司 (英国)
自我注射市场的最新发展
- 2024 年 9 月，Evotec 宣布与 Novo Nordisk 建立以细胞疗法为中心的技术开发合作伙伴关系后，股价上涨 6%。此次合作包括为德国和意大利的开发活动提供资金，以及预付款、潜在的里程碑成就和特许权使用费激励。Evotec 首席科学官 Cord Dohrmann 博士对通过这一合作伙伴关系创造创新的干细胞疗法表示乐观
- 2024 年 9 月，Tremfya (guselkumab) 获得 FDA 批准，用于治疗中度至重度活动性溃疡性结肠炎成人患者，此外还获准用于治疗斑块状银屑病和银屑病关节炎。它是首个针对该疾病的双效白细胞介素 23 抑制剂，在 QUASAR 研究中显示出显著的缓解率。以 200 毫克静脉诱导剂量给药，随后每 8 周皮下注射 100 毫克或每 4 周皮下注射 200 毫克维持剂量。此次批准彰显了强生致力于推进炎症性肠病治疗的承诺
- 2024 年 7 月，Biogen 收购了 Human Immunology Biosciences (HI-Bio)，通过有希望的治疗候选药物 felzartamab 增强了其免疫学产品线。此次收购将推动 felzartamab 进入针对各种适应症的 3 期试验。IgA 肾病和抗体介导排斥的 2 期研究报告了积极的中期结果
- 2024 年 7 月，Biogen 收购了 Human Immunology Biosciences (HI-Bio)，通过有希望的治疗候选药物 felzartamab 增强了其免疫学产品线。此次收购将推动 felzartamab 进入针对各种适应症的 3 期试验。IgA 肾病和抗体介导排斥的 2 期研究报告了积极的中期结果
- 2024 年 7 月，阿斯利康以高达 10.5 亿美元的价格成功收购了 Amolyt Pharma，增强了其 Alexion 罕见病产品线。其中包括用于治疗甲状旁腺功能减退症的 III 期肽类药物 eneboparatide，扩大了阿斯利康对罕见内分泌疾病和钙调节治疗的关注
- 2024 年 6 月，Aptar Digital Health 与 SHL Medical 合作，通过整合其 SaMD 平台增强联网设备技术。此次合作旨在改善患者在自行注射治疗过程中的体验，支持患者更好地遵守治疗并进行疾病管理
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE SELF-INJECTIONS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CUSTOMIZATIONS
5 EUROPE SELF-INJECTIONS MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.1.1 AUSTRALIA
5.1.2 CHINA
5.1.3 INDIA
5.2 REGULATORY SUBMISSIONS
5.2.1 PRE-SUBMISSION ACTIVITIES
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION
5.3 CLINICAL EVALUATION
5.4 REGULATORY SUBMISSION PREPARATION
5.5 SUBMISSION TO REGULATORY AUTHORITY
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY
5.7 APPROVAL AND MARKET AUTHORIZATION
5.8 POST-MARKET SURVEILLANCE
5.9 RENEWAL AND COMPLIANCE
5.1 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)
5.11 ADOPTION OF EUROPE STANDARDS (ISO AND IEC)
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE
5.13 CLINICAL DATA HARMONIZATION
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES
5.18 NORTH AMERICA REGULATORY SCENARIO
5.19 MEDICAL DEVICE CLASSIFICATION
5.2 REGULATORY SUBMISSIONS
5.21 EUROPE REGULATORY SCENARIO
5.22 REGULATORY SUBMISSIONS
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.24 SOUTH AMERICA REGULATORY SCENARIO
5.25 INTERNATIONAL HARMONIZATION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS
6.1.3 INCREASE IN PATIENT AUTONOMY
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS
6.2 RESTRAINTS
6.2.1 HIGH COST OF SELF INJECTORS
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE
6.4 CHALLENGES
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS
7 EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 SELF-INJECTION DEVICES
7.3 SELF-INJECTION FORMULATION
8 EUROPE SELF-INJECTIONS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 SINGLE DOSE
8.3 MULTI-DOSE
9 EUROPE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 SUBCUTANEOUS
9.3 INTRA MUSCULAR
9.4 OTHERS
10 EUROPE SELF-INJECTIONS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 AUTOIMMUNE DISEASES
10.3 PAIN MANAGEMENT
10.4 EMERGENCY DRUGS
10.5 ONCOLOGY
10.6 HORMONAL DISORDERS
10.7 OTHERS
11 EUROPE SELF-INJECTIONS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 EUROPE SELF-INJECTIONS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 EUROPE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 HOSPITAL PHARMACY
13.4 ONLINE PHARMACY
13.5 OTHERS
14 EUROPE SELF-INJECTIONS MARKET, BY REGION
14.1 EUROPE
15 EUROPE SELF-INJECTIONS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 NOVO NORDISK
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JOHNSON & JOHNSON SERVICES, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 BIOGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 AMGEN INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 SANOFI
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBVIE INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 COMPANY SHARE ANALYSIS
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENT
17.7 YPSOMED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ASTRAZENECA
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 APTARGROUP, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 BAYER
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CREDENCE MEDSYSTEMS, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DALI MEDICAL DEVICES
17.15.1 COMPANY SN.APSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENABLE INJECTIONS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 E3D ELCAM DRUG DELIVERY DEVICES
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 F. HOFFMANN-LA ROCHE LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 GSK PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 GERRESHEIMER AG
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 HASELMEIER
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 IPSEN BIOPHARMACEUTICALS, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENT
17.23 LILLY
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 MIDAS PHARMA GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 MERCK & CO., INC.,
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 NOVARTIS AG
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENTS
17.27 NEMERA
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 OWEN MUMFORD
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 PFIZER INC.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENT
17.30.5 RECENT DEVELOPMENT
17.31 PHILIP MEDSIZE
17.31.1 COMPANY SNAPSHOT
17.31.2 PRODUCT PORTFOLIO
17.31.3 RECENT DEVELOPMENTS
17.32 PHARMAJET.
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENT
17.33 PENJET
17.33.1 COMPANY SNAPSHOT
17.33.2 1.1.4 PRODUCT PORTFOLIO
17.33.3 RECENT DEVELOPMENT
17.34 RECIPHARM AB
17.34.1 COMPANY SNAPSHOT
17.34.2 PRODUCT PORTFOLIO
17.34.3 RECENT DEVELOPMENTS
17.35 SCHOTT PHARMA
17.35.1 COMPANY SNAPSHOT
17.35.2 PRODUCT PORTFOLIO
17.35.3 RECENT DEVELOPMENTS
17.36 SHL MEDICAL AG
17.36.1 COMPANY SNAPSHOT
17.36.2 PRODUCT PORTFOLIO
17.36.3 RECENT DEVELOPMENT
17.37 SOCIÉTÉ INDUSTRIELLE DE SONCEBOZ SA
17.37.1 COMPANY SNAPSHOT
17.37.2 PRODUCT PORTFOLIO
17.37.3 RECENT DEVELOPMENT
17.38 TERUMO CORPORATION
17.38.1 COMPANY SNAPSHOT
17.38.2 REVENUE ANALYSIS
17.38.3 PRODUCT PORTFOLIO
17.38.4 RECENT DEVELOPMENT
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.39.1 COMPANY SNAPSHOT
17.39.2 REVENUE ANALYSIS
17.39.3 PRODUCT PORTFOLIO
17.39.4 RECENT DEVELOPMENT
17.4 TEVA PHARMACEUTICALS
17.40.1 COMPANY SNAPSHOT
17.40.2 REVENUE
17.40.3 PRODUCT PORTFOLIO
17.40.4 RECENT DEVELOPMENT
17.41 UCB PHARMA
17.41.1 COMPANY SNAPSHOT
17.41.2 REVENUE
17.41.3 PRODUCT PORTFOLIO
17.41.4 RECENT DEVELOPMENT
17.42 WEST PHARMACEUTICAL SERVICES
17.42.1 COMPANY SNAPSHOT
17.42.2 REVENUE ANALYSIS
17.42.3 PRODUCT PORTFOLIO
17.42.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 5 EUROPE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 EUROPE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 EUROPE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 EUROPE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 EUROPE SELF-INJECTION FORMULATION IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 EUROPE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 11 EUROPE SINGLE DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 EUROPE MULTI-DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 EUROPE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 14 EUROPE SUBCUTANEOUS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 EUROPE INTRA MUSCULAR IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 EUROPE OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 EUROPE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 18 EUROPE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 EUROPE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 EUROPE PAIN MANAGEMENT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 EUROPE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 EUROPE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 EUROPE ONCOLOGY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 EUROPE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 EUROPE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 EUROPE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 28 EUROPE ADULT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 EUROPE GERIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 EUROPE PEDIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 EUROPE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 32 EUROPE MALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 33 EUROPE FEMALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 EUROPE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 EUROPE DIRECT TENDER IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 EUROPE HOSPITAL PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 37 EUROPE ONLINE PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 EUROPE OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 EUROPE SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 40 EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 41 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 43 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 44 EUROPE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 EUROPE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 EUROPE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 49 EUROPE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 50 EUROPE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 51 EUROPE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 EUROPE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 EUROPE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 55 EUROPE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 56 EUROPE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 GERMANY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 60 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 61 GERMANY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 GERMANY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 GERMANY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 GERMANY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 GERMANY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 66 GERMANY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 67 GERMANY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 GERMANY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 GERMANY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 GERMANY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 GERMANY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 72 GERMANY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 73 GERMANY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 74 U.K. SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 77 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 78 U.K. AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 U.K. PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.K. WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.K. NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.K. SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 83 U.K. SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 84 U.K. SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 85 U.K. AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.K. EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.K. HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 U.K. SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 89 U.K. SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 90 U.K. SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 FRANCE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 92 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 94 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 95 FRANCE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 FRANCE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 FRANCE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 FRANCE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 FRANCE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 100 FRANCE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 101 FRANCE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 FRANCE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 FRANCE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 FRANCE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 FRANCE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 106 FRANCE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 107 FRANCE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 ITALY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 111 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 112 ITALY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 ITALY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 ITALY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 ITALY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 ITALY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 117 ITALY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 118 ITALY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 119 ITALY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 ITALY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 ITALY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 ITALY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 123 ITALY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 124 ITALY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 125 SPAIN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 126 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 128 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 129 SPAIN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 SPAIN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SPAIN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 SPAIN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 SPAIN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 134 SPAIN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 135 SPAIN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 136 SPAIN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 SPAIN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 SPAIN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 SPAIN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 140 SPAIN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 141 SPAIN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 142 RUSSIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 143 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 145 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 146 RUSSIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 147 RUSSIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 RUSSIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 RUSSIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 RUSSIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 151 RUSSIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 152 RUSSIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 153 RUSSIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 RUSSIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 RUSSIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 RUSSIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 157 RUSSIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 158 RUSSIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 159 TURKEY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 160 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 162 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 163 TURKEY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 TURKEY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 TURKEY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 TURKEY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 TURKEY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 168 TURKEY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 169 TURKEY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 170 TURKEY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 171 TURKEY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 TURKEY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 TURKEY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 174 TURKEY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 175 TURKEY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 176 BELGIUM SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 177 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 179 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 180 BELGIUM AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 BELGIUM PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 182 BELGIUM WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 183 BELGIUM NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 BELGIUM SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 185 BELGIUM SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 186 BELGIUM SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 187 BELGIUM AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 BELGIUM EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 BELGIUM HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 BELGIUM SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 191 BELGIUM SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 192 BELGIUM SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 193 DENMARK SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 194 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 196 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 197 DENMARK AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 DENMARK PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 DENMARK WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 200 DENMARK NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 DENMARK SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 202 DENMARK SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 203 DENMARK SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 204 DENMARK AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 DENMARK EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 DENMARK HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 207 DENMARK SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 208 DENMARK SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 209 DENMARK SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 210 SWITZERLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 211 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 213 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 214 SWITZERLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 215 SWITZERLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 SWITZERLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 SWITZERLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 SWITZERLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 219 SWITZERLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 220 SWITZERLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 221 SWITZERLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 SWITZERLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 SWITZERLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 SWITZERLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 225 SWITZERLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 226 SWITZERLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 NETHERLANDS SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 228 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 230 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 231 NETHERLANDS AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 232 NETHERLANDS PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 NETHERLANDS WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 NETHERLANDS NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 235 NETHERLANDS SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 236 NETHERLANDS SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 237 NETHERLANDS SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 238 NETHERLANDS AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 NETHERLANDS EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 240 NETHERLANDS HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 NETHERLANDS SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 242 NETHERLANDS SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 243 NETHERLANDS SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 244 SWEDEN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 245 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 247 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 248 SWEDEN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 SWEDEN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 SWEDEN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 SWEDEN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 252 SWEDEN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 253 SWEDEN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 254 SWEDEN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 255 SWEDEN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 SWEDEN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 SWEDEN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 258 SWEDEN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 259 SWEDEN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 260 SWEDEN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 261 NORWAY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 262 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 264 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 265 NORWAY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 NORWAY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 NORWAY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 NORWAY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 269 NORWAY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 270 NORWAY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 271 NORWAY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 272 NORWAY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 NORWAY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 NORWAY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 NORWAY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 276 NORWAY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 277 NORWAY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 278 POLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 279 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 281 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 282 POLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 POLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 POLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 POLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 286 POLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 287 POLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 288 POLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 289 POLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 POLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 POLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 292 POLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 293 POLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 294 POLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 295 FINLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 296 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 298 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 299 FINLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 300 FINLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 FINLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 302 FINLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 FINLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 304 FINLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 305 FINLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 306 FINLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 307 FINLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 FINLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 FINLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 310 FINLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 311 FINLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 312 REST OF EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 EUROPE SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 2 EUROPE SELF-INJECTIONS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SELF-INJECTIONS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SELF-INJECTIONS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SELF-INJECTIONS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SELF-INJECTIONS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE SELF-INJECTIONS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE SELF-INJECTIONS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE SELF-INJECTIONS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SELF-INJECTIONS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 EUROPE SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 12 TWO SEGMENTS COMPRISE THE EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 EXECUTIVE SUMMARY
FIGURE 15 SELF-INJECTION DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SELF-INJECTIONS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 EUROPE SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 EUROPE SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 19 EUROPE SELF-INJECTIONS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 EUROPE SELF-INJECTIONS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 EUROPE SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2023
FIGURE 22 EUROPE SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2024-2031 (USD MILLION)
FIGURE 23 EUROPE SELF-INJECTIONS MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 24 EUROPE SELF-INJECTIONS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 25 EUROPE SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 26 EUROPE SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 27 EUROPE SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 28 EUROPE SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 EUROPE SELF-INJECTIONS MARKET: BY APPLICATION, 2023
FIGURE 30 EUROPE SELF-INJECTIONS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 31 EUROPE SELF-INJECTIONS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 32 EUROPE SELF-INJECTIONS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 EUROPE SELF-INJECTIONS MARKET: BY AGE GROUP, 2023
FIGURE 34 EUROPE SELF-INJECTIONS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 35 EUROPE SELF-INJECTIONS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 36 EUROPE SELF-INJECTIONS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 37 EUROPE SELF-INJECTIONS MARKET: BY GENDER, 2023
FIGURE 38 EUROPE SELF-INJECTIONS MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 39 EUROPE SELF-INJECTIONS MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 40 EUROPE SELF-INJECTIONS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 41 EUROPE SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 42 EUROPE SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 43 EUROPE SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 44 EUROPE SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 EUROPE SELF-INJECTIONS MARKET: SNAPSHOT (2023)
FIGURE 46 EUROPE SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
